Free Trial

ERYTECH Pharma (ERYP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
Average Volume
93,510 shs
Market Capitalization
$105.77 million
P/E Ratio
Dividend Yield
Price Target
ERYP stock logo

About ERYTECH Pharma Stock (NASDAQ:ERYP)

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

ERYP Stock News Headlines

Royalty Pharma PLC Class A RPRX
[36,483% Gain] Your 90 Day Gameplan
Ever caught yourself thinking, "there's got to be an easier way to crack this crypto code"? Well, you’re right. And today, I’m unveiling a game-changer.
[36,483% Gain] Your 90 Day Gameplan
Ever caught yourself thinking, "there's got to be an easier way to crack this crypto code"? Well, you’re right. And today, I’m unveiling a game-changer.
ERYTECH Responds to Akkadian’s Disinformation
See More Headlines
Receive ERYP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYTECH Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$32.66 million
Book Value
$0.80 per share


Free Float
Market Cap
$105.77 million
Not Optionable
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Gil Beyen M.B.A. (Age 61)
    CEO & Director
    Comp: $624.52k
  • Mr. Eric Soyer Ph.D. (Age 57)
    Deputy GM, CFO & COO
    Comp: $414.28k
  • Dr. Jérôme Bailly Pharm.D. (Age 44)
    Deputy GM of Operations, Chief Quality Officer & Qualified Person
    Comp: $270.47k
  • Naomi Eichenbaum
    Director Investor Relations
  • Ms. Anne-Cécile Fumey (Age 48)
    HR Director
  • Dr. Iman El-Hariry M.D. (Age 63)
    Ph.D., Chief Medical Officer
  • Ms. Karine Charton Ph.D.
    Director of Innovation & Valorization
  • Dr. Philip L. Lorenzi
    Consultant & Member of Scientific Board
  • Prof. Eric Raymond M.D.
    Ph.D., Consultant & Member of Scientific Board
  • Dr. Bridget Bax
    Consultant & Member of Scientific Board

ERYP Stock Analysis - Frequently Asked Questions

When did ERYTECH Pharma IPO?

ERYTECH Pharma (ERYP) raised $125 million in an IPO on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

What other stocks do shareholders of ERYTECH Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ERYTECH Pharma investors own include Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Sesen Bio (SESN), Cidara Therapeutics (CDTX), Fate Therapeutics (FATE) and Gilead Sciences (GILD).

This page (NASDAQ:ERYP) was last updated on 7/17/2024 by Staff

From Our Partners